MAPK1 and colonic neoplasm: We therefore treated HT29 human colon cancer cells with a selective inhibitor of ERK known as VTX‐11e (Aronov et al., 2009) in combination with CCT068127; we then determined the effect on cell proliferation and survival after 4 days and calculated synergy using a well‐established method (Chou and Talalay, 1984).